Barr expecting
This article was originally published in The Tan Sheet
Executive Summary
CEO Bruce Downey believes Barr has "met the standard the FDA laid out for us in the letter denying our [Plan B switch] application a few months ago," the exec said Feb. 2, explaining the firm's expectation of receiving an "approvable letter" from the agency. "We followed the recommendation, we followed the pathway that was sort of suggested in that letter, I think we have done it...professionally, done it appropriately and we have met all reasonable objections." FDA failed to act on the application by the PDUFA deadline of Jan. 21 (1"The Tan Sheet" Jan. 24, 2005, p. 6)...
You may also be interested in...
No Plan B Switch Parade As User Fee Deadline Comes And Goes
FDA will deliver a decision in the "near future" on whether the Plan B emergency contraceptive pill is "approvable" for over-the-counter use in women age 16 and up, according to manufacturer Barr Labs
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.